Anne-Marie Taburet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne-Marie Taburet has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Isabelle Vincent
Clinical Pharmacy Department, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris,1 Department of Immunology, Hôpital Georges Pompidou, Assistance Publique-Hôpitaux de Paris,2 Department of Virology, Hôpital Pitié Salpétrière, Assistance Publique-Hôpitaux de Paris,4 Department of Infectious Diseases Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris,5 Department of Virology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris,6 INSERM SC10, Villejuif, France3
2 shared publicationsAurélie Barrail
Assistance Publique Hôpitaux de Paris (AP-HP)
1 shared publicationCatherine Gillotin
Glaxo Wellcome Laboratory, Marly-le-Roi, France
1 shared publicationCecile Goujard
Internal Medicine Department, Bicetre Hospital, Le Kremlin Bicetre, France
1 shared publicationCharles Olaro
Medical and Administrative Hospital Direction, Arua Regional Referral Hospital, Arua, Uganda
1 shared publication- Christine Rouzioux
CHU Necker, Laboratoire de Virologie, Université Paris Descartes, Paris bService des Maladies Infectieuses et Tropicales, CHR d'Orléans-La Source, Orléans cInstitut Pasteur, Unité de Régulation des Infections Rétrovirales, Paris, France
1 shared publication
Latest Publications
- Open Access
- 26 July 2011
- Published by Springer Nature in BMC Pediatrics
- Vol. 11 (1) , 67
Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda
Children living with HIV continue to be in urgent need of combined antiretroviral therapy (ART). Strategies to scale up and improve pediatric HIV care in resource-poor regions, especially in sub-Saharan Africa, require further research from these settings. We describe treatment outcomes in children treated in rural Uganda after 1 and 2 years of ART start.
- 26 July 2011
- Published by Springer Nature in BMC Pediatrics
- Vol. 11 (1) , 67
Open AccessImmunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda
Children living with HIV continue to be in urgent need of combined antiretroviral therapy (ART). Strategies to scale up and improve pediatric HIV care in resource-poor regions, especially in sub-Saharan Africa, require further research from these settings. We describe treatment outcomes in children treated in rural Uganda after 1 and 2 years of ART start.
- 1 January 2005
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 44 (10) , 1035-1050
Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir
The efficacy of HIV-1 protease inhibitors (PIs) as part of highly active antiretroviral therapy is now well established and has provided benefits to many patients with HIV infection. Atazanavir is a new azapeptide PI compound that was recently approved in the US and Europe. Atazanavir is recommended in combination with other antiretroviral agents for the treatment of HIV-1 infection. Atazanavir is rapidly absorbed and administration of a single dose of atazanavir with a light meal resulted in a 70% increase in area under the plasma concentration-time curve (AUC); therefore atazanavir should be taken with food. Atazanavir is 86% bound to human serum protein independently of concentration. Concentration in body fluids appeared to be lower than plasma concentration. Like other PIs, atazanavir is extensively metabolised by hepatic cytochrome P450 (CYP) 3A isoenzymes. The mean terminal elimination half-life in healthy volunteers was approximately 7 hours at steady state following administration of atazanavir 400mg daily with a light meal. When atazanavir 300mg was coadministered with ritonavir 100mg on a once-daily dosage regimen, atazanavir AUC from 0 to 24 hours and minimum plasma concentration were increased by 3- to 4-fold and approximately 10-fold, respectively, compared with atazanavir 300mg alone. Therefore, ritonavir boosted atazanavir regimen (ritonavir 100mg and atazanavir 300mg once daily) is increasingly favoured in some patients. Efavirenz, a potent CYP3A inducer, decreased atazanavir concentrations by 75% and, unexpectedly, tenofovir, a nucleotide reverse transcriptase inhibitor, decreased atazanavir concentrations by 25%. Average predose concentrations in HIV-infected patients who received atazanavir 400mg once daily were 273 ng/mL, which was believed to be several-fold higher than protein-binding corrected 50% inhibitory concentration of wildtype viruses. In HIV-infected patients who received once-daily ritonavir (100mg) boosted atazanavir (300mg), mean (±SD) trough concentration was 862 (±838) ng/mL. Several clinical trials showed the efficacy of atazanavir 400mg once daily with a nucleoside analogue backbone in antiretroviral-naive patients. The atazanavir 300/ritonavir 100mg once-daily combination coadministered with other antiretrovirals showed the efficacy of this strategy in patients receiving efavirenz or in moderately antiretroviral-experienced HIV-infected patients. Recommended once-daily doses of atazanavir taken with food are either 400mg or 300mg in combination with low dose ritonavir (100mg) in moderately antiretroviral-experienced patients. Major advantages of atazanavir to date are its simplicity of administration (once-daily administration) and its less undesirable effect on the lipid profiles in patients.
- 1 January 2005
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 44 (10) , 1035-1050
Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir
The efficacy of HIV-1 protease inhibitors (PIs) as part of highly active antiretroviral therapy is now well established and has provided benefits to many patients with HIV infection. Atazanavir is a new azapeptide PI compound that was recently approved in the US and Europe. Atazanavir is recommended in combination with other antiretroviral agents for the treatment of HIV-1 infection. Atazanavir is rapidly absorbed and administration of a single dose of atazanavir with a light meal resulted in a 70% increase in area under the plasma concentration-time curve (AUC); therefore atazanavir should be taken with food. Atazanavir is 86% bound to human serum protein independently of concentration. Concentration in body fluids appeared to be lower than plasma concentration. Like other PIs, atazanavir is extensively metabolised by hepatic cytochrome P450 (CYP) 3A isoenzymes. The mean terminal elimination half-life in healthy volunteers was approximately 7 hours at steady state following administration of atazanavir 400mg daily with a light meal. When atazanavir 300mg was coadministered with ritonavir 100mg on a once-daily dosage regimen, atazanavir AUC from 0 to 24 hours and minimum plasma concentration were increased by 3- to 4-fold and approximately 10-fold, respectively, compared with atazanavir 300mg alone. Therefore, ritonavir boosted atazanavir regimen (ritonavir 100mg and atazanavir 300mg once daily) is increasingly favoured in some patients. Efavirenz, a potent CYP3A inducer, decreased atazanavir concentrations by 75% and, unexpectedly, tenofovir, a nucleotide reverse transcriptase inhibitor, decreased atazanavir concentrations by 25%. Average predose concentrations in HIV-infected patients who received atazanavir 400mg once daily were 273 ng/mL, which was believed to be several-fold higher than protein-binding corrected 50% inhibitory concentration of wildtype viruses. In HIV-infected patients who received once-daily ritonavir (100mg) boosted atazanavir (300mg), mean (±SD) trough concentration was 862 (±838) ng/mL. Several clinical trials showed the efficacy of atazanavir 400mg once daily with a nucleoside analogue backbone in antiretroviral-naive patients. The atazanavir 300/ritonavir 100mg once-daily combination coadministered with other antiretrovirals showed the efficacy of this strategy in patients receiving efavirenz or in moderately antiretroviral-experienced HIV-infected patients. Recommended once-daily doses of atazanavir taken with food are either 400mg or 300mg in combination with low dose ritonavir (100mg) in moderately antiretroviral-experienced patients. Major advantages of atazanavir to date are its simplicity of administration (once-daily administration) and its less undesirable effect on the lipid profiles in patients.
- Open Access
- 1 June 2004
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (6) , 2091-2096
Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients
The aim of the present study was to assess the pharmacokinetic behavior of atazanavir-ritonavir when it is coadministered with tenofovir disoproxil fumarate (DF) in human immunodeficiency virus (HIV)-infected patients. Eleven patients enrolled in Agence Nationale de Recherche sur le SIDA (National Agency for AIDS Research, Paris, France) trial 107 were included in this pharmacokinetic study. They received atazanavir at 300 mg and ritonavir at 100 mg once a day (QD) from day 1 to the end of study. For the first 2 weeks, their nucleoside analog reverse transcriptase inhibitor (NRTI) treatments remained unchanged. Tenofovir DF was administered QD from day 15 to the end of the study. Ongoing NRTIs were selected according to the reverse transcriptase genotype of the HIV isolates from each patient. The values of the pharmacokinetic parameters for atazanavir and ritonavir were measured before (day 14 [week 2]) and after (day 42 [week 6]) initiation of tenofovir DF and are reported for the 10 patients who completed the study. There was a significant decrease in the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) for atazanavir with the addition of tenofovir DF (AUC 0-24 ratio, 0.75; 90% confidence interval, 0.58 to 0.97; P = 0.05). There was a trend for a decrease in the minimum concentrations of atazanavir and ritonavir in plasma when they were combined with tenofovir, but none of the differences reached statistical significance. The median decreases in the HIV RNA loads at week 2 and week 6 were 0.1 and 0.2 log copies/ml, respectively. In summary, our data are consistent with the existence of a significant interaction between atazanavir and tenofovir DF.
- 1 June 2004
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (6) , 2091-2096
Open AccessInteractions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients
The aim of the present study was to assess the pharmacokinetic behavior of atazanavir-ritonavir when it is coadministered with tenofovir disoproxil fumarate (DF) in human immunodeficiency virus (HIV)-infected patients. Eleven patients enrolled in Agence Nationale de Recherche sur le SIDA (National Agency for AIDS Research, Paris, France) trial 107 were included in this pharmacokinetic study. They received atazanavir at 300 mg and ritonavir at 100 mg once a day (QD) from day 1 to the end of study. For the first 2 weeks, their nucleoside analog reverse transcriptase inhibitor (NRTI) treatments remained unchanged. Tenofovir DF was administered QD from day 15 to the end of the study. Ongoing NRTIs were selected according to the reverse transcriptase genotype of the HIV isolates from each patient. The values of the pharmacokinetic parameters for atazanavir and ritonavir were measured before (day 14 [week 2]) and after (day 42 [week 6]) initiation of tenofovir DF and are reported for the 10 patients who completed the study. There was a significant decrease in the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) for atazanavir with the addition of tenofovir DF (AUC 0-24 ratio, 0.75; 90% confidence interval, 0.58 to 0.97; P = 0.05). There was a trend for a decrease in the minimum concentrations of atazanavir and ritonavir in plasma when they were combined with tenofovir, but none of the differences reached statistical significance. The median decreases in the HIV RNA loads at week 2 and week 6 were 0.1 and 0.2 log copies/ml, respectively. In summary, our data are consistent with the existence of a significant interaction between atazanavir and tenofovir DF.
- 1 January 2003
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 42 (14) , 1179-1191
Once-Daily Administration of Antiretrovirals
Adherence to therapy is of critical importance for the long-term success of the treatment of HIV infection. Once-daily administration of antiretroviral agents is appealing, as it may increase patient’s adherence. The pharmaceutical industry is making huge efforts to develop drugs or combinations of drugs with pharmacokinetic properties allowing once-daily administration. The major pharmacokinetic requirement for once-daily administration is that the intracellular concentration of the antiretroviral or its active metabolite remains above the minimal concentration that can inhibit viral replication during the entire 24-hour period. Soon, all three major classes of antiretroviral agents will be available as once-daily formulations. However, only a few clinical trials have yet assessed the efficacy and safety of truly once-daily antiretroviral combinations. Preliminary results from these small pilot studies suggest that once-daily administration of antiretrovirals is a feasible approach. Large comparative trials are needed before the real benefits of such a strategy can be fully assessed.
- 1 January 2003
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 42 (14) , 1179-1191
Once-Daily Administration of Antiretrovirals
Adherence to therapy is of critical importance for the long-term success of the treatment of HIV infection. Once-daily administration of antiretroviral agents is appealing, as it may increase patient’s adherence. The pharmaceutical industry is making huge efforts to develop drugs or combinations of drugs with pharmacokinetic properties allowing once-daily administration. The major pharmacokinetic requirement for once-daily administration is that the intracellular concentration of the antiretroviral or its active metabolite remains above the minimal concentration that can inhibit viral replication during the entire 24-hour period. Soon, all three major classes of antiretroviral agents will be available as once-daily formulations. However, only a few clinical trials have yet assessed the efficacy and safety of truly once-daily antiretroviral combinations. Preliminary results from these small pilot studies suggest that once-daily administration of antiretrovirals is a feasible approach. Large comparative trials are needed before the real benefits of such a strategy can be fully assessed.
- Open Access
- 1 January 2003
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (1) , 118-123
Steady-State Pharmacokinetics of Amprenavir Coadministered with Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients
The protease inhibitor (PI) ritonavir is used as a strong inhibitor of cytochrome P450 3A4, which boosts the activities of coadministered PIs, resulting in augmented plasma PI levels, simplification of the dosage regimen, and better efficacy against resistant viruses. The objectives of the present open-label, multiple-dose study were to determine the steady-state pharmacokinetics of amprenavir administered at 600 mg twice daily (BID) and ritonavir administered at 100 mg BID in human immunodeficiency virus type 1 (HIV-1)-infected adults treated with different antiretroviral combinations including or not including a nonnucleoside reverse transcriptase inhibitor (NNRTI). Nineteen patients completed the study. The steady-state mean minimum plasma amprenavir concentration ( C min,ss ) was 1.92 μg/ml for patients who received amprenavir and ritonavir without an NNRTI and 1.36 μg/ml for patients who received amprenavir and ritonavir plus efavirenz. For patients who received amprenavir-ritonavir without an NNRTI, the steady-state mean peak plasma amprenavir concentration ( C max,ss ) was 7.12 μg/ml, the area under the concentration-time curve from 0 to 10 h (AUC 0-10 ) was 32.06 μg · h/ml, and the area under the concentration-time curve over a dosing interval (12 h) at steady-state (AUC ss ) was 35.74 μg · h/ml. Decreases in the mean values of C min,ss (29%), C max,ss (42%), AUC 0-10 (42%), and AUC ss (40%) for amprenavir occurred when efavirenz was coadministered with amprenavir-ritonavir. No unexpected side effects were observed. As expected, coadministration of amprenavir with ritonavir resulted in an amprenavir C min,ss markedly higher than those previously reported for the marketed dose of amprenavir. When amprenavir-ritonavir was coadministered with efavirenz, amprenavir-ritonavir maintained a mean amprenavir C min,ss above the mean 50% inhibitory concentration of amprenavir previously determined for both wild-type HIV-1 isolates and HIV-1 strains isolated from PI-experienced patients. These data support the use of low-dose ritonavir to enhance the level of exposure to amprenavir and increase the efficacy of amprenavir.
- 1 January 2003
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (1) , 118-123
Open AccessSteady-State Pharmacokinetics of Amprenavir Coadministered with Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients
The protease inhibitor (PI) ritonavir is used as a strong inhibitor of cytochrome P450 3A4, which boosts the activities of coadministered PIs, resulting in augmented plasma PI levels, simplification of the dosage regimen, and better efficacy against resistant viruses. The objectives of the present open-label, multiple-dose study were to determine the steady-state pharmacokinetics of amprenavir administered at 600 mg twice daily (BID) and ritonavir administered at 100 mg BID in human immunodeficiency virus type 1 (HIV-1)-infected adults treated with different antiretroviral combinations including or not including a nonnucleoside reverse transcriptase inhibitor (NNRTI). Nineteen patients completed the study. The steady-state mean minimum plasma amprenavir concentration ( C min,ss ) was 1.92 μg/ml for patients who received amprenavir and ritonavir without an NNRTI and 1.36 μg/ml for patients who received amprenavir and ritonavir plus efavirenz. For patients who received amprenavir-ritonavir without an NNRTI, the steady-state mean peak plasma amprenavir concentration ( C max,ss ) was 7.12 μg/ml, the area under the concentration-time curve from 0 to 10 h (AUC 0-10 ) was 32.06 μg · h/ml, and the area under the concentration-time curve over a dosing interval (12 h) at steady-state (AUC ss ) was 35.74 μg · h/ml. Decreases in the mean values of C min,ss (29%), C max,ss (42%), AUC 0-10 (42%), and AUC ss (40%) for amprenavir occurred when efavirenz was coadministered with amprenavir-ritonavir. No unexpected side effects were observed. As expected, coadministration of amprenavir with ritonavir resulted in an amprenavir C min,ss markedly higher than those previously reported for the marketed dose of amprenavir. When amprenavir-ritonavir was coadministered with efavirenz, amprenavir-ritonavir maintained a mean amprenavir C min,ss above the mean 50% inhibitory concentration of amprenavir previously determined for both wild-type HIV-1 isolates and HIV-1 strains isolated from PI-experienced patients. These data support the use of low-dose ritonavir to enhance the level of exposure to amprenavir and increase the efficacy of amprenavir.